When eczema therapy must be paused, biologics tolerate it better than oral drugs

Design

Systematic review and network meta-analysis; GRADE-assessed

Population

55 studies; network of 9 studies, 26 pairwise comparisons, 2,585 observations across 13 regimens

Primary outcome

Sustained EASI75 at 16–52 weeks after withdrawal, dose reduction or interval extension

Effect

Early relapse after oral withdrawal; biologics sustained remission; lebrikizumab lowest risk of EASI75 loss

Systemic atopic dermatitis therapy sometimes has to be interrupted — for pregnancy, vaccination, infection or cost. This network meta-analysis asked how remission holds up under withdrawal, dose reduction or longer dosing intervals compared with continuing, pooling 55 studies with a network built from nine studies and 13 regimens.

Stopping oral therapies led to early relapse of disease activity, whereas biologics sustained remission even after prolonged withdrawal or extended dosing intervals. Within the biologics, lebrikizumab withdrawal and interval extension carried the lowest risk of losing an EASI75 response, though that specific ranking comes from a sparse network and is less certain than the broad oral-versus-biologic pattern.

The usable message is about how to pause, not whether to treat. If a patient on a JAK inhibitor or ciclosporin needs a break, expect relapse sooner and plan cover or a faster review. On a biologic, an interruption or a stretched interval is more likely to hold — useful for the woman planning pregnancy or the patient facing a supply or cost gap.

• Discontinuing oral systemic therapy (such as JAK inhibitors or ciclosporin) risked early relapse of atopic dermatitis.
• Biologics sustained remission even after prolonged withdrawal or extended dosing intervals.
• Lebrikizumab had the lowest risk of losing EASI75 response, but from a sparse, less certain network.
• When a break is needed, plan closer review after stopping an oral drug; a biologic interruption is more likely to hold.

Why it matters

It turns an everyday problem — how to interrupt therapy safely — into a decision guided by drug class rather than guesswork.

Don't overread it

The specific ranking favouring one biologic comes from a sparse network; treat the class-level message as firmer than any single-drug claim.

The statistics, in plain English

This network meta-analysis compares treatments partly through indirect links; the broad finding — orals relapse early, biologics hold — rests on more data than the drug-specific lebrikizumab ranking, which comes from only nine networked studies and is correspondingly shakier.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.